N-(m-PEG4)-N'-(PEG4-NHS ester)-Cy5 is a polyethylene glycol (PEG)-based linker commonly employed in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].
Fmoc-N-amido-PEG2-alcohol is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.
Lenalidomide-4-aminomethyl is a CRBN ligand derived from Lenalidomide, which is utilized for the recruitment of CRBN protein. By linking Lenalidomide-4-aminomethyl to the ligand, a PROTAC can be formed.
Propargyl-PEG5-1-o-b-cyanoethyl-nn-diisopropylphosphoramidite is a polyethylene glycol (PEG)-based linker molecule specifically designed for the synthesis of proteolysis-targeting chimeras (PROTACs).
PROTAC CDK9 degrader-4 is a potent and efficacious chemical compound designed specifically to degrade CDK9, a protein involved in transcription regulation. This compound effectively targets and reduces the levels of CDK9, thereby modulating transcriptional activity.
Negative control for TBK1 PROTAC 3i. Binds TBK1 with high affinity, but exhibits no significant degradation of TBK1. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
PROTAC IRAK4 degrader-4 (US20190192668A1, compound I-127) is a Cereblon-based PROTAC specifically designed to target and degrade interleukin-1 receptor-associated kinase 4 (IRAK4).
Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus a short PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 11 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
BMS-1166-N-piperidine-COOH is a chemical compound that functions as the BMS-1166-based moiety. It binds to the E3 ligase ligand through a linker, leading to the formation of PROTAC PD-1 PD-L1 degrader-1, which facilitates the degradation of PD-1 PD-L1. BMS-1166 demonstrates potent inhibition of PD-1 PD-L1 interaction, with an IC 50 of 1.4 nM. By antagonizing the inhibitory effect of the PD-1 PD-L1 immune checkpoint on T cell activation, BMS-1166 promotes T cell activation.